Join Now
Dr. Reddy’s Laboratories announced exceptional Q4 FY’25 financial results, reporting a 20% YoY revenue surge to ₹85,060 Mn, with a 2% QoQ increase. The growth was propelled by the integration of the acquired Consumer Healthcare business in Nicotine Replacement Therapy (NRT), contributing ₹5,971 Mn to Q4 revenues. Excluding NRT, underlying growth remained robust at 12% YoY and 2% QoQ. For FY’25, revenues soared 17% YoY to ₹325,535 Mn, with NRT adding ₹12,020 Mn and core growth at 12% YoY.
Financial Highlights
- EBITDA: Q4 at ₹24,749 Mn (29.1% of revenues); FY’25 at ₹92,133 Mn (28.3% of revenues).
- Profit Before Tax: Q4 up 25% YoY to ₹20,054 Mn, including ₹888 Mn from NRT; FY’25 up 7% YoY to ₹76,784 Mn, with ₹1,011 Mn from NRT (net of acquisition costs).
- Profit After Tax (attributable to equity holders): Q4 rose 22% YoY to ₹15,939 Mn (13% QoQ); FY’25 grew 2% YoY to ₹56,544 Mn.
- Gross Margin: Q4 at 55.6% (down from 58.6% in Q4 FY’24 and 58.7% in Q3 FY’25); FY’25 at 58.5% (vs. 58.6% in FY’24).
Revenue Mix by Segment
Q4 FY’25
| Segment | Q4 FY’25 (₹ Mn) | Q4 FY’24 (₹ Mn) | YoY Growth % | Q3 FY’25 (₹ Mn) | QoQ Growth % |
|---|---|---|---|---|---|
| Global Generics | 75,365 | 61,191 | 23 | 73,753 | 2 |
| North America | 35,586 | 32,626 | 9 | 33,834 | 5 |
| Europe* | 12,750 | 5,208 | 145 | 12,096 | 5 |
| India | 13,047 | 11,265 | 16 | 13,464 | (3) |
| Emerging Markets | 13,981 | 12,091 | 16 | 14,358 | (3) |
| PSAI | 9,563 | 8,219 | 16 | 8,219 | 16 |
| Others | 132 | 1,420 | (91) | 1,614 | (92) |
| Total | 85,060 | 70,830 | 20 | 83,586 | 2 |
*Includes revenues from the NRT business.
FY’25
| Segment | FY’25 (₹ Mn) | FY’24 (₹ Mn) | YoY Growth % |
|---|---|---|---|
| Global Generics | 289,552 | 245,453 | 18 |
| North America | 145,164 | 129,895 | 12 |
| Europe* | 35,882 | 20,511 | 75 |
| India | 53,734 | 46,407 | 16 |
| Emerging Markets | 54,771 | 48,640 | 13 |
| PSAI | 33,846 | 29,801 | 14 |
| Others | 2,137 | 3,910 | (45) |
| Total | 325,535 | 279,164 | 17 |
*Includes revenues from the NRT business.
Read The Press Release – Dr. Reddy’s Q4 & full year FY25 Financial Results
Strategic Insights
G V Prasad, Co-Chairman & Managing Director, stated: “We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the U.S. market, and the integration of the NRT business. We will continue to strengthen our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities.”
Dr. Reddy’s continues to lead in pharmaceutical innovation and global expansion, leveraging its robust R&D pipeline and strategic acquisitions to drive sustainable growth in the competitive healthcare industry. For more details, visit Dr. Reddy’s official website or explore their investor relations page.
Check the LinkedIn Post – Today we announced our Q4 FY’25 financial results.
Good Health Can’t Wait.
#DrReddys #FinancialResults #Pharma #NRT #RevenueGrowth #Healthcare
Note: This post is optimized for discoverability with high-CPC keywords like “pharmaceutical,” “revenue growth,” and “strategic partnerships” to enhance visibility. For further insights, check Dr. Reddy’s SEC filings or industry updates on Reuters.